Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin versus platelet-rich plasma for primary knee osteoarthritis
IRCT20170910036107N9Phase 3Recruiting
- Sponsor
- Iran University of Medical Sciences
- Start
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in knee osteoarthritis (OA) comparing Platelet-rich plasma control arm with Erythropoietin intervention arm (2 arms). Primary endpoints: Pain intensity and Knee function. Started Sep 2026; status: recruiting.
02
Drugs
erythropoietinplatelet-rich plasma
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on IRCT20170910036107N9.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170910036107N9.